Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

Chill factor: Cardiac-related admissions, mortality increase in the winter months

Two studies suggest patients with cardiac-related hospitalizations—specifically for aortic dissection and ST-segment elevation myocardial infarction (STEMI)—are admitted more frequently and have higher mortality rates during winter months.

Less is more? Double antithrombotic therapy sufficient for AFib patients after PCI

A new meta-analysis found double antithrombotic therapy following PCI for patients with atrial fibrillation (AFib) was associated with 47 percent fewer bleeding events than triple therapy and similar rates of major adverse cardiac events.

Thumbnail

American Airlines sued after passenger dies after in-flight pulmonary embolism

The family of a newlywed nurse is suing American Airlines after she fell ill on a flight and died. The cause of her death was determined to be an acute massive pulmonary embolism and cardiogenic shock.

Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes

TITUSVILLE, N.J., April 27, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of a real-world study showing that adults with type 2 diabetes initiated on INVOKANA® (canagliflozin) 300mg had significantly better blood glucose control, based on A1C goal attainment and reduction, compared to similar patients initiated on Farxiga®(dapagliflozin) 10mg.

Thumbnail

Prediabetes, hypertension combo increases risk of cardiovascular disease

A combination of prediabetes and hypertension increases the risk for cardiovascular disease (CVD) more than either risk factor alone, according to new research published April 18 in Hypertension.

Thumbnail

CULPRIT-SHOCK confirmed: Another study supports culprit-only PCI

A retrospective study of patients with acute MI complicated by cardiogenic shock presented at SCAI 2018 supported the message from the randomized CULPRIT-SHOCK trial: culprit lesion PCI is associated with lower mortality than multivessel revascularization.

Thumbnail

Researchers develop first tool to predict readmission rates after TAVR

The first-ever risk score for predicting 30-day readmission rates in patients undergoing transcatheter aortic valve replacement (TAVR) can be easily folded into electronic medical records and inform perioperative care decisions, researchers reported at the Society for Cardiovascular Angiography and Interventions 2018 Scientific Sessions.

Two-Year Feasibility Study Results Encouraging with Medtronic Harmony(TM) Transcatheter Pulmonary Valve

DUBLIN and SAN DIEGO — April 26, 2018 — Medtronic plc (NYSE: MDT) today announced two-year outcomes for the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study. Presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 41st Annual Scientific Sessions, data from 18 patients followed out to two years revealed the Harmony TPV showed solid valve function and no paravalvular leak (PVL).